1. Home
  2. IVR vs MNPR Comparison

IVR vs MNPR Comparison

Compare IVR & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INVESCO MORTGAGE CAPITAL INC

IVR

INVESCO MORTGAGE CAPITAL INC

HOLD

Current Price

$7.83

Market Cap

732.4M

Sector

Real Estate

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$96.71

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IVR
MNPR
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
732.4M
587.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
IVR
MNPR
Price
$7.83
$96.71
Analyst Decision
Buy
Strong Buy
Analyst Count
2
11
Target Price
$8.25
$107.00
AVG Volume (30 Days)
2.6M
144.8K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
17.80%
N/A
EPS Growth
N/A
54.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$150.63
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.10
$29.18
52 Week High
$9.50
$105.00

Technical Indicators

Market Signals
Indicator
IVR
MNPR
Relative Strength Index (RSI) 44.93 83.34
Support Level $7.76 $52.92
Resistance Level $7.92 $103.17
Average True Range (ATR) 0.13 6.06
MACD -0.00 2.84
Stochastic Oscillator 21.62 93.86

Price Performance

Historical Comparison
IVR
MNPR

About IVR INVESCO MORTGAGE CAPITAL INC

Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: